RxDoctor Payments Data

Robert Williams, MD

Urology · Muncie, INNPI 1851339709

Payments from drug & device makers

What this record shows

This record is dominated by other: $22,071 of the $33,355 with a category attached, or 66.2%. Central Indiana URS Consumables, LLC accounts for 66.2% of it on its own, with 54 other manufacturers making up the rest. Reporting peaked in 2024 at $16,656 and has fallen 52.7% since, to $7,876 in 2025. Among urology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,355in general payments, 2019–2025

Across 512 payments — averaging $65.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Central Indiana URS Consumables, LLC$22K
  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$2K
  • Johnson & Johnson$762
  • Bayer$648
  • Rochester Medical Corporation$536
  • plus $6K from 49 others
$2,834in research payments, 2019–2025

Across 2 payments — averaging $1417.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$3K
$15,600in ownership & investment interests, 2019–2025

Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Central Indiana URS Consumables, LLC$16K

What the payments were for

  • Travel & lodging$4981%
  • Food & beverage$10,31231%
  • Education$4731%
  • Other$22,07166%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,355 in reported general payments places this provider in the 90th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$138,695
Medicare patients
404
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide45$490,078
XtandiEnzalutamide31$361,444
OrgovyxRelugolix47$127,040
MyrbetriqMirabegron123$95,042
Thiola EcTiopronin12$91,001
GemtesaVibegron64$71,198
ElmironPentosan Polysulfate Sodium14$21,215
Mirabegron ErMirabegron17$16,774
Tamsulosin Hcl484$6,594
Finasteride331$5,190
Tolterodine Tartrate ErTolterodine Tartrate35$3,881
Potassium Citrate ErPotassium Citrate18$2,711
Bethanechol Chloride64$2,431
Estradiol36$2,126
NitrofurantoinNitrofurantoin Macrocrystal73$2,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$648$490,07845 claims
Astellas Pharma US IncXtandi, Myrbetriq$1,704$456,485154 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$482$198,238111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 272 urology providers in Indiana.

Other urology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →